+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Forecast 2024-2030- Product Image
Global Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Forecast 2024-2030- Product Image
Sale

Global Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5592101
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023, USD 12.77 billion in 2024, and is expected to grow at a CAGR of 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments.

Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling.

Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, reflecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

Market Trends by Segment

  • Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
  • Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
  • Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
  • Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers

Agilent Technologies Inc. has entered into a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore to accelerate translational cancer research on Asian-prevalent cancers over the next two years. As part of this agreement, Agilent has supplied an automated NGS library preparation platform, enabling investigations into the genomic details specific to Asian cancer cohorts.

Sophia Genetics, Agilent Partner on Cancer Analysis Product

Sophia Genetics, a leader in data-driven medicine, has recently announced a long-term partnership with Agilent Technologies, allowing them to develop a new cancer analysis product. This new product will enable clinicians to use patient’s genomic profiling information for smarter and more efficient care decisions. Through this endeavor, both companies are working towards making personalized cancer treatments faster and more accessible. With their product, doctors can move from the traditional trial-and-error approach of prescribing drugs to one tailored and precisely matches therapeutic agents to the tumor's genetics. The longer-term research is underway as well, which could help serve as an important resource for future cancer studies.

Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer

Point32Health and Foundation Medicine have recently taken a major step forward in providing comprehensive genomic profiling for members with advanced cancer. By expanding access to this technology, individuals will now receive tailored treatments that can increase their chances of responding to the therapy needed for successful treatment outcomes. This initiative will increase human-recoded data levels and provide a more personalized approach to cancer treatments, leading the way in providing the best possible care for those fighting the disease. With Foundation Medicine's mission to accelerate precision medicine and Point32Health's dedication to making complex molecular information accessible, these two organizations are positioned as game changers when advancing cancer treatments.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc.

This research report offers invaluable insights into various crucial aspects of the Cancer/Tumor Profiling Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
5.1.1.3. Surging preference for personalized medicines for cancer treatment
5.1.2. Restraints
5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
5.1.3. Opportunities
5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
5.1.4. Challenges
5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Market Segmentation Analysis
5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
5.3. Market Trend Analysis
5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
6. Cancer/Tumor Profiling Market, by Technology
6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Polymerase Chain Reaction
7. Cancer/Tumor Profiling Market, by Biomarker Type
7.1. Introduction
7.2. Genomic Biomarker
7.3. Protein Biomarker
8. Cancer/Tumor Profiling Market, by Cancer Type
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma Cancer
8.6. Prostate Cancer
9. Cancer/Tumor Profiling Market, by Application
9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring
10. Americas Cancer/Tumor Profiling Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer/Tumor Profiling Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
13.3.5. ??Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
13.3.9. Prenetics Acquires ACT Genomics
13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENOMIC BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MELANOMA CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLINICAL APPLICATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SCREENING, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TREATMENT & MONITORING, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 83. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 84. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 85. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 86. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 87. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 88. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 89. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 90. CANADA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 91. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 92. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 93. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 94. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 95. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 96. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 97. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. MEXICO CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 100. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 110. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 112. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 119. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 120. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 121. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 122. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 123. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 124. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 127. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 128. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 129. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 130. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 131. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 132. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 133. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 134. CHINA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 135. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 136. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 137. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 138. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 139. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 140. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 141. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 142. INDIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 143. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 144. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 145. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 146. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 147. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 148. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 149. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 150. INDONESIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 151. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 152. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 153. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 154. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 155. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 156. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 157. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 158. JAPAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 159. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 160. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 161. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 162. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 163. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 164. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 165. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 166. MALAYSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 167. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 168. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 169. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 170. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 171. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 172. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 173. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 174. PHILIPPINES CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 175. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 176. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 177. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 178. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 179. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 180. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 181. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 182. SINGAPORE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 183. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 184. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 185. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 186. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 187. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 188. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 189. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 190. SOUTH KOREA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 191. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 192. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 193. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 194. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 195. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 196. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 197. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 198. TAIWAN CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 199. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 200. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 201. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 202. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 203. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 204. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 205. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 206. THAILAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 207. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 208. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 209. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 210. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 211. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 212. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 213. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 214. VIETNAM CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 225. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 226. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 227. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 228. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 229. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 230. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 231. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. DENMARK CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 234. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 235. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 236. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 237. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 238. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 239. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 240. EGYPT CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 241. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 242. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 243. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 244. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 245. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 246. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 247. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 248. FINLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 249. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 250. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 251. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 252. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 253. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 254. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 255. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 256. FRANCE CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 257. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 258. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 259. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 260. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 261. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 262. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 263. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 264. GERMANY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 265. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 266. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 267. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 268. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 269. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 270. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 271. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 272. ISRAEL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 273. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 274. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 275. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 276. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 277. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 278. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 279. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 280. ITALY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 281. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 282. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 283. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 284. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 285. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 286. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 287. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 288. NETHERLANDS CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 289. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 290. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 291. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 292. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 293. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 294. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 295. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 296. NIGERIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 297. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 298. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 299. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 300. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 301. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 302. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 303. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 304. NORWAY CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 305. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 306. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 307. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 308. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 309. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 310. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 311. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 312. POLAND CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 313. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 314. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 315. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 316. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 317. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 318. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 319. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 320. QATAR CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 321. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 322. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 323. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 324. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 325. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 326. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 327. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 328. RUSSIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 330. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
TABLE 332. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
TABLE 334. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 336. SAUDI ARABIA CANCER/TUMOR PROFILING MARKET SIZE,

Companies Mentioned

  • 4basecare Onco Solutions Private Limited
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • BostonGene Corporation
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENINUS Inc.
  • Genomic Life
  • GenScript Biotech Corporation
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • IMBdx, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Neogenomics, Inc.
  • Nonacus Limited
  • OncoDNA S.A.
  • Oncompass Medicine Hungary Kft.
  • Paragon Genomics, Inc.
  • Personalis, Inc.
  • Perthera, Inc.
  • Predictive Oncology Inc.
  • Strand Life Sciences
  • Sysmex Corporation
  • Takara Bio Inc.
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 12.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 35.94 Billion
Compound Annual Growth Rate18.7%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO) - Global Forecast to 2030 - Product Image

Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO) - Global Forecast to 2030

  • Report
  • 270 Pages
  • Global
From
Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product and Place, with Executive and Consultant Guides - Product Image

Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product and Place, with Executive and Consultant Guides

  • Report
  • 303 Pages
  • Global
From
Genomic Biomarker Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Genomic Biomarker Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 104 Pages
  • Global
From
Cancer Biomarkers Market: Industry Trends and Global Forecasts 2024-2035: Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions - Product Image

Cancer Biomarkers Market: Industry Trends and Global Forecasts 2024-2035: Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions

  • Report
  • 309 Pages
  • Global
From
United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032 - Product Image

United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032

  • Report
  • 160 Pages
  • United States
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.